[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"progressive-supranuclear-palsy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:progressive-supranuclear-palsy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,45,77,130,154,188,208,247,272,308,333,361,383,425,447,474,498,520,548],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100303052","investigating-complex-neurodegenerative-disorders-related-to-amyotrophic-lateral-sclerosis-and-frontotemporal-dementia-100303052",false,"NCT03225144","Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia","* INCLUSION CRITERIA:\n\nPatients will be included if they\n\n* Are age 18 or older\n* Have been given a diagnosis by a neurologist of frontotemporal dementia, primary progressive aphasia, semantic dementia, motor neuron disorder, amyotrophic lateral sclerosis, progressive bulbar palsy, corticobasal syndrome, Huntington disease or other related adult-onset neurodegenerative disorder OR\n* Carry a mutation in a gene that causes familial ALS or FTD\n\nEXCLUSION CRITERIA:\n\nPatients will be excluded if they\n\n* Have other major neurological or medical diseases that may cause progressive weakness or cognitive dysfunction, such as structural brain or spinal cord disease, metabolic diseases, paraneoplastic syndromes, infectious diseases, peripheral neuropathy or radiculopathy or other significant neurological abnormalities.\n* Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe\n* Require daytime ventilator support at the time of study entry\n* Are unable to travel to NIH\n* Patients with pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, or shrapnel fragments, metal fragments in the eye) will not be excluded but will not undergo magnetic resonance imaging.\n* Patients with tattoos above the neck or permanent make up will be excluded from undergoing 7T MRI.","ALL","18 Years","110 Years",{"count":19,"type":20},360,"ESTIMATED","OBSERVATIONAL","Background:\n\nNeurodegenerative disorders can lead to problems in movement or memory. Some can cause abnormal proteins to build up in brain cells. Researchers want to understand whether these diseases have related causes or risk factors.\n\nObjective:\n\nTo test people with movement or thinking and memory problems to see if they are eligible for research studies.\n\nEligibility:\n\nPeople ages 18 and older with a neurodegenerative disorder associated with accumulation of TDP-43 or Tau proteins\n\nDesign:\n\nParticipants will have a screening visit. This may take place over 2-3 days. Tests include:\n\nMedical history\n\nPhysical exam\n\nQuestions about behavior and mood\n\nTests of memory, attention, concentration, and thinking\n\nMovement measurement. The speed at which participants can stand up from a chair, tap their finger and foot, and walk a short distance will be measured. Some movements will be videotaped. They will be videotaped while they speak and read a paragraph.\n\nBlood tests. This might include genetic testing.\n\nLung and breathing tests\n\nMRI. They will lie on a table that slides into a cylinder that takes pictures of the body. Some participants will get a dye through IV.\n\nElectromyography. A thin needle will be inserted into the muscles to measure electrical signals.\n\nNerve tests. Small electrodes on the skin record muscle and nerve activity.\n\nA small piece of skin may be removed.\n\nA skin or blood sample may be taken to create stem cells.\n\nOptional lumbar puncture. A needle will be inserted into the space between the bones of the back to collect fluid.\n\nIf participants are not eligible for current studies, they may be contacted in the future.",[24,25,26],"Frontotemporal Dementia","Amyotrophic Lateral Sclerosis","Progressive Supranuclear Palsy",[28,26,29,24,30,31],"TDP-43","Motor Neuron Disease","Corticobasal Syndrome","Natural History","RECRUITING","2026-06-27",{"date":35,"type":36},"2026-06-30","ACTUAL",{"date":38,"type":36},"2017-10-11",{"date":40,"type":20},"2027-10-30",{"name":42,"class":43},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100636786","individualized-transcranial-magnetic-stimulation-in-parkinsonian-disorders-100636786","NCT07570212","Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders","Exploration of the Efficacy of Individualized Transcranial Magnetic Stimulation in the Treatment of Parkinsonian Disorders","Inclusion Criteria:\n\n1. Diagnostic Criteria Clinically established or clinically probable Parkinson's Disease (PD) according to the 2015 International Parkinson and Movement Disorder Society (MDS) diagnostic criteria; Clinically established or clinically probable Multiple System Atrophy (MSA) according to the 2022 MDS diagnostic criteria; Clinically probable or clinically possible Progressive Supranuclear Palsy (PSP) according to the 2017 MDS diagnostic criteria.\n2. Demographics Aged 30 to 80 years, inclusive; no gender restrictions.\n3. Disease Severity and Staging PD: Modified Hoehn and Yahr (H-Y) stage 2-4; MSA: Unified Multiple System Atrophy Rating Scale (UMSARS) Part IV stage 1-4; PSP: Modified Rankin Scale (mRS) grade 2-4.\n4. Informed Consent and Compliance Ability to understand and comply with the study requirements and provide written informed consent.\n\nExclusion Criteria:\n\n1. Contraindications to TMS Presence of intracranial metallic implants or other foreign bodies, including but not limited to cochlear implants, cardiac pacemakers, or internal metallic\u002Fmagnetic fragments.\n2. Contraindications to EEG and MRI EEG: Known allergy to conductive paste or other EEG-related contraindications. MRI: History of claustrophobia, presence of MRI-incompatible implants, or extensive tattoos.\n3. Concurrent Physical Therapies Currently receiving Transcranial Magnetic Stimulation (TMS) or other therapeutic physical modalities, such as Transcranial Direct Current Stimulation (tDCS).\n4. Unstable Medical Conditions Presence of unstable systemic diseases requiring urgent pharmacological or surgical intervention.\n5. Neurological and Psychiatric History Personal or family history of epilepsy; History of moderate-to-severe psychiatric or psychological disorders; Chronic insomnia or regular use of sedative-hypnotics; Current use of medications that significantly alter central nervous system excitability.","30 Years","80 Years",{"count":55,"type":20},50,"INTERVENTIONAL",[58],"NA","This clinical trial aims to evaluate whether individualized targeted repetitive transcranial magnetic stimulation (rTMS) can improve motor and non-motor symptoms in patients with parkinsonian disorders. The main question it aims to answer is:\n\n* Does individualized targeted rTMS alleviate symptoms of parkinsonian disorders?\n* Which clinical manifestations of parkinsonian syndromes are responsive to individualized targeted rTMS, and to what degree?\n\nProcedures:\n\n* Preparation (Screening) Participants will undergo clinical assessments, MRI, and EEG before the treatment.\n* Treatment (2 Weeks) Participants will receive a 10-day TMS treatment (once daily, Monday-Friday). Each treatment day takes approximately 3-4 hours. Participants need to keep stable medications and rehabilitation routines during this time.\n* Follow-up (10 Weeks) Participants will undergo follow-up assessments at the end of treatment and 10 weeks after treatment. Assessments include clinical scales, MRI, and EEG.",[61,62,26],"Parkinson's Disease","Multiple System Atrophy",[64,65,66],"parkinsonian disorders","transcranial magnetic stimulation","somato-cognitive action network","2026-06-24",{"date":69,"type":36},"2026-06-29",{"date":71,"type":36},"2025-12-22",{"date":73,"type":20},"2027-12-22",{"name":75,"class":76},"Peking University First Hospital","OTHER",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":56,"phases":87,"briefSummary":88,"conditions":89,"keywords":113,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":129},"100270060","neurologic-stem-cell-treatment-study-100270060","NCT02795052","Neurologic Stem Cell Treatment Study","Neurologic Bone Marrow Derived Stem Cell Treatment Study","NEST","Inclusion Criteria:\n\n1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.\n2. Be at least 6 months post-onset of the disease.\n3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.\n4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n5. Be over the age of 18 and capable of providing informed consent.\n6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.\n2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.\n3. Patients must be capable of providing informed consent.\n4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .\n5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.\n6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.",{"count":86,"type":20},500,[58],"This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1\u002F3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http:\u002F\u002Fmdstemcells.com\u002Fnest\u002F",[90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,26,105,25,106,107,108,109,24,110,111,112],"Neurologic Disorders","Nervous System Diseases","Neurodegenerative Diseases","Neurological Disorders","Stroke","Traumatic Brain Injury","Cadasil","Chronic Traumatic Encephalopathy","Cerebral Infarction","Cerebral Ischemia","Cerebral Stroke","Cerebral Hemorrhage","Parkinson","Multi-System Degeneration","MSA - Multiple System Atrophy","ALS","Neuropathy","Diabetic Neuropathies","Alzheimer Disease","Dementia","Lewy Body Disease","Cognitive Impairment","Lewy Body Variant of Alzheimer Disease",[114,115,94,95,116,117,106,118,99,111,109,119],"Neurologic Disease","Cerebral Vascular Accident","Multiple Sclerosis","Parkinsons Disease","Diabetic Neuropathy","Neurodegeneration",{"date":121,"type":36},"2026-06-26",{"date":123,"type":36},"2016-06",{"date":125,"type":20},"2028-07-31",{"name":127,"class":128},"MD Stem Cells","INDUSTRY",3,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":136,"sex":15,"minAge":137,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":56,"phases":140,"briefSummary":141,"conditions":142,"keywords":143,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":44},"100255570","a-molecular-anatomic-imaging-analysis-of-tau-in-progressive-supranuclear-palsy-100255570","NCT02605785","A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy","Inclusion Criteria:\n\n* Must be over 35 years of age and present with gradual progression of PSP-related symtoms\n* Must have an informant or study partner that can provide independent information of functioning.\n* Must meet criteria for possible or probable Progressive Supranuclear Palsy. To fulfill criteria for possible PSP, subjects must have a gradually progressive disorder with either vertical (upward or downward) supranuclear palsy or both slowing of vertical saccades and prominent postural instability with falls in the first year of disease onset. To fulfill criteria for probable PSP, subjects must have vertical (upward or downward gaze) supranuclear palsy and prominent postural instability with falls in the first year of disease onset.\n\nExclusion Criteria:\n\n* Subjects will be excluded if they meet criteria for another neurodegenerative disease (including corticobasal syndrome, frontotemporal dementia, primary progressive aphasia, Alzheimer's disease, multiple system atrophy and Parkinson's disease) or do not have the symptoms necessary to fulfill inclusion criteria for possible PSP.\n* Subjects with concurrent illnesses that could account for their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes will be excluded.\n* Women that are pregnant or post-partum and breast-feeding will be excluded.\n* Subjects will be excluded from the study if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome.\n* Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts), or if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy).\n* Subjects will also be excluded if they do not have an informant, or do not consent to research.",true,"35 Years",{"count":139,"type":20},332,[58],"This study is designed to learn more about overall tau burden in the brain of patients with Progressive Supranuclear Palsy (PSP).",[26],[144],"PSP","2026-04-29",{"date":147,"type":36},"2026-05-05",{"date":149,"type":4},"2015-11",{"date":151,"type":20},"2030-01",{"name":153,"class":76},"Mayo Clinic",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":136,"sex":15,"minAge":161,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":56,"phases":165,"briefSummary":166,"conditions":167,"keywords":176,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":187},"100299199","the-swedish-biofinder-2-study-100299199","NCT03174938","The Swedish BioFINDER 2 Study","BioFINDER2","COHORT A: Cognitively healthy younger individuals (40-65 years of age) INCLUSION CRITERIA\n\n* Age 40-65 years\n* Absence of cognitive symptoms as assessed by a physician with special interest in cognitive disorders.\n* MMSE score 27-30 at screening visit.\n* Do not fulfill the criteria for MCI or any dementia according to DSM-V.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Significant neurological or psychiatric illness.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT B: Cognitively healthy elderly individuals (66-100 years of age) INCLUSION CRITERIA\n\n* Age 66-100 years\n* Absence of cognitive symptoms as assessed by a physician with special interest in cognitive disorders.\n* MMSE score 26-30 at screening visit.\n* Do not fulfill the criteria for MCI or any dementia according to DSM-V.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Significant neurological or psychiatric illness.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT C: Subjective cognitive decline and mild cognitive impairment INCLUSION CRITERIA\n\n* Age 40-100 years.\n* Referred to the memory clinics due to cognitive symptoms experienced by the patient and\u002For informant. These symptoms do not have to be memory complaints, but could also be executive, visuospatial, language, praxis, psychomotor or social cognitive complaints.\n* MMSE score of 24 - 30 points.\n* Do not fulfill the criteria for any dementia (major neurocognitive disorder) according to DSM-V.\n* The medical doctor (after clinical assessments, cognitive testing, CSF analyses and structural brain imaging) believes the cognitive complaints are caused by an incipient neurocognitive disorder of any sort. This is defined as any case fulfilling the criteria above (i.e. both SCD and MCI) with an abnormal CSF Aβ42\u002F40 ratio, which is strongly associated with brain Aβ pathology and prodromal Alzheimer's disease. Further, cases with MCI (=minor neurocognitive impairment) due to either Parkinson's disease, Lewy body disease, vascular neurocognitive disorder or frontotemporal dementia (please see Appendix below for clinical criteria and references) can also be included.\n* Speaks and understands Swedish to the extent that an interpreter is not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT D: Dementia due to Alzheimer's disease INCLUSION CRITERIA\n\n* Age 40-100 years.\n* Referred to the memory clinics due to cognitive symptoms experienced by the patient and\u002For informant. These symptoms do not have to be memory complaints, but could also be executive, visuospatial, language, praxis or psychomotor complaints.\n* MMSE score of 12-26 points.\n* Fulfill the criteria for dementia (major neurocognitive disorder) due to Alzheimer's disease (DSM-V).\n* Speaks and understands Swedish to the extent that an interpreter was not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Refusing lumbar puncture, MRI or PET.\n\nCOHORT E: Other dementias INCLUSION CRITERIA\n\n* Age 40-100 years.\n* Fulfill the criteria for dementia (major neurocognitive disorder) due to FTD, PDD, DLB or subcortical VaD alternatively the criteria for PD, PSP, MSA, CBS or ALS.\n* Speaks and understands Swedish to the extent that an interpreter was not necessary for the patient to fully understand the study information and cognitive tests.\n\nEXCLUSION CRITERIA\n\n* Significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study.\n* Current significant alcohol or substance misuse.\n* Refusing lumbar puncture, MRI or PET.","20 Years","100 Years",{"count":164,"type":20},2950,[58],"The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g. to characterize the role of beta-amyloid pathology in early diagnosis of Alzheimer's disease (AD) using amyloid-PET (18F-Flutemetamol) and Aβ analysis in cerebrospinal fluid samples. The BioFINDER 1 study has resulted in more than 40 publications during the last three years, many in high impact journals, and some the of the results have already had important implications for the diagnostic work-up patients with AD in the clinical routine practice.\n\nThe original BioFINDER 1 cohort started to include participants in 2008. Since then there has been a rapid development of biochemical and neuroimaging technologies which enable novel ways to the study biological processes involved in Alzheimer's disease in living people. There has also been a growing interest in the earliest stages of AD and other neurodegenerative diseases. With the advent of new tau-PET tracers there is now an opportunity to elucidate the role of tau pathology in the pathogenesis of AD and other tauopathies. The Swedish BioFINDER 2 study has been designed to complement the BioFINDER 1 study and to e.g. address issues regarding the role of tau pathology in different dementias and in preclinical stages of different dementia diseases. Further, the clinical assessments and MRI methods have been further optimized compared to BioFINDER 1. Detailed assessments of motor aspects and dual task performance, which is part of a sub-study named Motor-ACT: \"Motor aspects and activities in relation to cognitive decline and brain pathologies, has been added to further optimize assessment of motor function.",[109,108,168,110,169,170,171,172,26,173,62,174,175],"Parkinson Disease","Parkinson-Dementia Syndrome","Frontotemporal Degeneration","Semantic Dementia","Progressive Nonfluent Aphasia","Corticobasal Degeneration","Mild Cognitive Impairment","ALS (Amyotrophic Lateral Sclerosis)",[177],"Early diagnosis, biomarker, PET, MRI, β-amyloid, tau, CSF, cognitive test","2026-04-01",{"date":180,"type":36},"2026-04-06",{"date":182,"type":36},"2017-05-15",{"date":184,"type":20},"2036-12",{"name":186,"class":76},"Skane University Hospital",2,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":136,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":44},"100352687","facilitating-diagnostics-and-prognostics-of-parkinsonian-syndromes-using-neuroimaging-100352687","NCT03872102","Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging","Quantitative Diagnostics of Parkinsonian Syndromes Using Multi-modal Neuroimaging and Deep Learning","Inclusion Criteria:\n\nFor Aim 1:\n\n* Diagnosis of Parkinson disease\n* Existence of sufficient clinical data from previous UTS Southwestern longitudinal study to determine progression rate (categorized as fast or slow)\n* Availability of suitable matched participant in the alternate progression group (fast or slow)\n* Willingness to participate in the imaging studies required for this study and to provide written informed consent\n\nFor Aim 2:\n\nPD subjects will be recruited in accordance with the MDS Clinical Diagnostic Criteria for PD.\n\n* Duration of PD (since diagnosis) is \\\u003C 5 years\n* Willing to participate in imaging and clinical scoring visits, and provide written informed consent\n* Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move)\n\nMSA subjects will be recruited in accordance with the Second Consensus Statement on Diagnosis of Multiple System Atrophy.\n\n* Duration of MSA (since diagnosis) is \\\u003C 5 years\n* Willing to participate in imaging and clinical scoring visits, and provide written informed consent\n* Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move away during the study)\n\nPSP subjects will be recruited in accordance with the MDS Criteria for Diagnosis of Progressive Supranuclear Palsy and must meet the designation of \"probable PSP\" for inclusion.\n\n* Willing to participate in imaging and clinical scoring visits, and provide written informed consent\n* Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move away during the study)\n\nControl subjects will be recruited who meet the following criteria:\n\n* Roughly age and sex matched with the subjects in the PD cohort\n* No history or examination findings suggestive of any neurodegenerative disease\n* Normal gait, balance, and eye movements for age\n* No clinical evidence for symptomatic orthostatic hypotension\n* Willing to participate in imaging and clinical scoring visits, and provide written informed consent\n* Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move away during the study)\n\nExclusion Criteria:\n\nFor Aims 1 and 2:\n\n* Any contraindications to undergoing the multimodal imaging program\n* All females of child-bearing potential, between the ages of 18-55, will be excluded from the study, unless they are confirmed to be not pregnant with a pregnancy test prior to scanning\n* This study will require constant clear communication throughout the duration of the study; therefore, non-English speakers will be excluded\n* Right-handed finger amputees\n* Cast on right hand or fingers at the time of enrollment\n* Has clinically significant liver, kidney, lung, metabolic or hormone disturbances which pose safety risk\n* Has a current clinically significant heart disease that poses a safety risk\n* Has a current clinically significant infectious disease or a medical comorbidity which poses a safety risk\n* Has a history of relevant severe drug allergy or hypersensitivity\n* Have a history of drug, alcohol, or substance dependence or abuse within the last year, or prior prolonged history of dependence or abuse\n* Currently undergoing chemotherapy or radiation for cancer\n* Recreational drug use in past six months\n* Central nervous systems disease or brain injury that would preclude participation in this study\n* Psychiatric or neurological disorder that would preclude participation in this study\n* Inability to keep or maintain research appointments\n\nFor Aim 1:\n\n* Severe disease progression such that participation in the imaging tests would be impossible or difficult\n* Non-availability of a suitable matched participant in the alternate progression group (fast or slow)\n\nFor Aim 2:\n\nPD subjects\n\n1. Unequivocal cerebellar abnormalities\n2. Downward vertical gaze limitation or slowing of downward saccades\n3. Diagnosis of behavioral variant frontotemporal dementia or primary progressive aphasia\n4. Parkinsonian features restricted to the lower limbs for \\> 3 years\n5. Treatment with dopamine blockers or depleters in a time course consistent with drug induced parkinsonism\n6. Absence of an observable response to high dose levodopa despite moderate disease severity\n7. Expert considers a diagnosis of alternative syndrome more likely than PD\n8. Rapid progression of gait impairment requiring wheelchair within 5 years of onset\n9. Complete absence of progression of motor symptoms over 5 years unless due to treatment\n10. Early bulbar dysfunction within the first 5 years since diagnosis\n11. Inspiratory respiratory dysfunction (stridor or frequent sighs)\n12. Severe autonomic failure in the first 5 years\n13. Recurrent falls (\\>1 per year) because of impaired balance in the first 3 years\n14. Disproportionate dystonic anterocollis or hand contractures of hands or feet within 10 years\n15. Absence of any of the common non-motor features of PD despite 5 years of disease\n16. Otherwise unexplained pyramidal tract signs (weakness, hyperreflexia, or extensor toe signs)\n17. Bilateral symmetric parkinsonism\n\nMSA subjects\n\n1. Clinically significant neuropathy\n2. Hallucinations not induced by drugs\n3. Onset after age 75 years\n4. Family history of ataxia or parkinsonism\n5. White matter lesions suggesting multiple sclerosis\n\nPSP subjects\n\n1. Predominant, otherwise unexplained impairment of episodic memory, suggestive of AD (Alzheimer's disease)\n2. Predominant, otherwise unexplained autonomic failure, e.g., orthostatic hypotension (orthostatic reduction in blood pressure after 3 minutes standing \\> 30 mm Hg systolic or \\> 15 mm Hg diastolic), suggestive of multiple system atrophy or Lewy body disease\n3. Predominant, otherwise unexplained visual hallucinations or fluctuations in alertness, suggestive of dementia with Lewy bodies\n4. Predominant, otherwise unexplained multisegmental upper and lower motor neuron signs, suggestive of motor neuron disease (pure upper motor neuron signs are not an exclusion criterion)\n5. Sudden onset or step-wise or rapid progression of symptoms, in conjunction with corresponding imaging or laboratory findings, suggestive of vascular etiology, autoimmune encephalitis, metabolic encephalopathies, or prion disease\n6. History of encephalitis\n7. Prominent appendicular ataxia\n8. Identifiable cause of postural instability, e.g., primary sensory deficit, vestibular dysfunction, severe spasticity, or lower motor neuron syndrome\n\nControl subjects\n\na. In the investigator's opinion, an unsuitable candidate to serve as a control",{"count":196,"type":20},90,"The goals of this study are: 1) to identify biomarkers using neuroimaging that are associated with progression rate using statistical methods, and 2) to identify biomarkers that are associated with the differential diagnosis of Parkinson's disease and atypical parkinsonism.",[168,62,26],"2026-01-25",{"date":201,"type":36},"2026-01-27",{"date":203,"type":36},"2019-03-28",{"date":205,"type":20},"2026-12-31",{"name":207,"class":76},"University of Texas Southwestern Medical Center",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":136,"sex":15,"minAge":137,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":216,"conditions":217,"keywords":232,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":44},"100565858","the-curepsp-genetics-program-100565858","NCT06647641","The CurePSP Genetics Program","Inclusion Criteria:\n\n1. Adults (aged 35 or older) with a clinical diagnosis of PSP, CBS, MSA, or a related neurological disease as confirmed by their healthcare provider, or unaffected family members of participants who have reported a family history of relevant neurodegenerative conditions.\n2. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Possible or Probable PSP (32), clinically established or clinically probable MSA (33), Armstrong criteria (2013) for possible or probable CBS (34). Diagnostic certainty will be determined by the treating\u002Freferring clinician.\n3. Willingness to undergo genetic testing. Participants will have the option to receive relevant genetic test results.\n4. Have the capacity to give full informed consent in writing or electronically, or provide consent through a legally authorized representative (LAR)\u002Fpower of attorney (POA), and have read, understood, and completed the informed consent form.\n5. Are able to perform or have a designee who can perform study activities (including completion of either online or orally administered surveys).\n\nExclusion Criteria:\n\n1. Individuals who have received a blood transfusion within the past 3 months.\n2. Individuals who have active hematologic malignancies such as lymphoma or leukemia.\n3. Individuals who have had a bone marrow transplant within the past 5 years.\n4. Individuals under the age of 35 or age of majority in applicable states at the time of consenting.",{"count":215,"type":20},1000,"This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.\n\nUp to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using non-CLIA-approved whole genome sequencing at the National Institutes of Health. Pathogenic variants that are deemed possibly related to these conditions will be confirmed using CLIA-approved testing. The study involves minimal risk to participants.",[144,218,30,219,220,173,221,222,223,104,224,62,225,226,227,228,229,26,230,231],"PSP - Progressive Supranuclear Palsy","Corticobasal Syndrome(CBS)","Corticobasal Degeneration Syndrome","Corticobasal Degeneration (CBD)","Corticobasal Syndrome (CBS)","MSA","MSA-C","Multiple System Atrophy (MSA) With Orthostatic Hypotension","Multiple System Atrophy - Cerebellar Subtype (MSA-C)","Multiple System Atrophy - Parkinsonian Subtype (MSA-P)","Multiple System Atrophy, Cerebellar Type","Multiple System Atrophy, Parkinsonian Type","Progressive Supranuclear Palsy(PSP)","Progressive Supranuclear Palsy (PSP)",[233,26,62,234,235,144,223,236,237],"genetic study","Corticobasal","CurePSP","CBD","Genes","2026-01-12",{"date":240,"type":36},"2026-01-14",{"date":242,"type":36},"2024-10-08",{"date":244,"type":20},"2030-12-31",{"name":246,"class":76},"Massachusetts General Hospital",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":144,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":56,"phases":256,"briefSummary":257,"conditions":258,"keywords":260,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":44},"100615367","tdcs-as-treatment-for-motor-function-100615367","NCT07291687","tDCS as Treatment for Motor Function","Transcranial Direct Current Stimulation as a Treatment for Motor Function in Participants Living With Progressive Supranuclear Palsy, Corticalbasal Syndrome Degeneration, or Parkinson's Disease","Inclusion Criteria:\n\n\\- 1. Participants must be able to walk unassisted, or with the assistance of a walker or cane, and be individuals who walk daily.\n\n2\\. Participants should have a sufficient level of English to be able to express themselves verbally, be able to read and follow instructions.\n\nExclusion Criteria:\n\n* 3\\. Individuals with metal implants within the brain such as shunts will be excluded.",{"count":255,"type":20},20,[58],"Previous preliminary results are sufficiently impressive to suggest that tDCS stimulation does have the potential to improve motor function when that ability is trained during stimulation. In the proposed study, the investigation will assess whether walking sessions combined with tDCS lead to improvements in motor function: gait, articulation, eye gaze, and motor dexterity. In addition, the investigators wish to examine if such results can be replicated in people with other conditions, such as cortical basal syndrome, and Parkinson's disease.",[26,259,168],"Cortical Basal Ganglionic Degeneration",[261,262],"Progressive Supranuclear Palsy (PSP),","Cortical basal syndrome (CBD)","2025-12-05",{"date":265,"type":36},"2025-12-18",{"date":267,"type":36},"2025-10-30",{"date":269,"type":20},"2030-12",{"name":271,"class":76},"Baycrest",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":279,"enrollmentInfo":280,"targetDuration":281,"studyType":21,"phases":4,"briefSummary":282,"conditions":283,"keywords":287,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":307},"100556794","improving-prognostic-confidence-in-neurodegenerative-diseases-causing-dementia-using-peripheral-biomarkers-and-integrative-modeling-100556794","NCT06529744","Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling","CRND TorCA","Inclusion Criteria:\n\n* Possible or probable diagnosis of MCI or early dementia\n* Age 30-95\n* Study partner who has some weekly contact with patient. Some of the neuropsychological assessment require collateral from close contacts to assess cognition and functioning. Since neurodegenerative diseases can be associated with reduced cognition, including reduced awareness of one's own impairments, participants will be assessed for their capacity to consent at all study visits.\n* Must, in the opinion of the site investigator, be able to complete most study procedures.\n\nExclusion Criteria:\n\n* Participants who are not able to complete the majority of assessments in the opinion of the PI are excluded from the study. Exclusion criteria are evaluated at the site investigator's discretion; if the site investigator believes that the participant's symptoms are due to causes other than neurodegeneration, despite the presence of an exclusionary condition, the investigator may overrule the exclusion.","95 Years",{"count":86,"type":20},"1 Year","To develop a model to predict disease progression in a large cohort of patients across a variety of neurodegenerative diseases, including Mild Cognitive Impairment (MCI) and dementia due to any neurodegenerative disease, including Alzheimer's Disease (AD), Lewy Body Disease (LBD), Vascular Disease (VaD) and Frontotemporal lobar degeneration (FTLD).",[109,108,284,285,24,174,30,26,168,286],"Dementia With Lewy Bodies","Vascular Dementia","Primary Progressive Aphasia",[288,289,290,291,292,293,294,295,296,297],"alzheimer's disease","dementia","dementia with lewy bodies","vascular dementia","frontotemporal dementia","mild cognitive impairment","corticobasal syndrome","progressive supranuclear palsy","parkinson's disease","primary progressive aphasia","2025-11-17",{"date":300,"type":36},"2025-11-20",{"date":302,"type":36},"2023-11-11",{"date":304,"type":20},"2027-11",{"name":306,"class":76},"University Health Network, Toronto",4,{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":136,"sex":15,"minAge":16,"maxAge":315,"enrollmentInfo":316,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":44},"100285367","gait-analysis-in-neurological-disease-100285367","NCT02994719","Gait Analysis in Neurological Disease","Gait Pattern Analysis in Neurological Disease","Inclusion Criteria:\n\n* Age 18-85 (for both healthy and affected subjects).\n* Presence of at least 2 of the following: bradykinesia, rest tremor, rigidity, postural instability (UK PD Brain Bank Criteria) (Affected subjects only).\n* Montreal Cognitive Assessment will be employed to determine whether subjects will need the assent of a legally authorized representative. Subjects with MOCA ≤ 21 will be consented only with the assent of the subject and informed consent of the authorized legal representative (Affected subjects only).\n* These may include subjects who may have indeterminate parkinsonism, when it is not clear whether they have idiopathic Parkinson's Disease versus one of the Atypical Parkinsonisms, such as Vascular Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy, Normal Pressure Hydrocephalus or Corticobasal Degeneration (Affected subjects only).\n* Subjects with assistive devices will be eligible for the study and may use them during the study (Affected subjects only).\n* Absence of complaints regarding difficulty walking such as arthritic pain, fatigue during walking or slowness of walking (Healthy subjects only).\n\nExclusion Criteria:\n\n* Presence of alternative explanation for parkinsonism such as head trauma, drug-induced parkinsonism (affected subjects only).\n* Currently being treated for major medical illness requiring recent hospitalization (\\\u003C14 days) (for both healthy and affected subjects).\n* Currently participating in another clinical study with an intervention arm (for both healthy and affected subjects).\n* Inability to consent due to cognitive impairment and absence of legally authorized representative (for both healthy and affected subjects).\n* Subjects with any cardiac, pulmonary conditions (congestive heart failure requiring hospitalization within the past 90 days, recent myocardial infarction \\\u003C 90 days, supplemental oxygen-requiring subjects due to cardiac or pulmonary conditions) that limit their ability to safely participate in a walking trial (for both healthy and affected subjects).","85 Years",{"count":317,"type":20},120,"The purpose of this study is to investigate whether speed-dependent measures of gait can be identified in patients with neurological conditions that affect gait, particularly in subjects with parkinsonian disorders.",[61,320,321,26,62,173,322,323],"Parkinsonian Disorders","Atypical Parkinson Disease","Gait, Frontal","Huntington Disease","2025-06-05",{"date":326,"type":36},"2025-06-08",{"date":328,"type":36},"2016-03-01",{"date":330,"type":20},"2026-06-20",{"name":332,"class":76},"Beth Israel Deaconess Medical Center",{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":343,"conditions":344,"keywords":345,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":358,"locationsCount":360},"100416712","systematic-assessment-of-laryngopharyngeal-function-in-patients-with-neurodegenerative-diseases-100416712","NCT04706234","Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative Diseases","Prospective Observational Study for the Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative Diseases","FEEMSA","Inclusion Criteria:\n\n* diagnosis of probable or possible multiple system atrophy according to current consensus criteria (Gilman et al. 2008) or\n* diagnosis of probable or possible PSP according to the the Movement Disorders Society (MDS) diagnostic criteria (Höglinger et al. 2017) or\n* diagnosis of Parkinson's disease according to the MDS diagnostic criteria (Postuma et al 2015)\n* Hoehn and Yahr Stage within the range of I-V or\n* diagnosis of motor neurone disease or\n* diagnosis of a neurodegenerative disease other than specified above\n\nAND underwent laryngopharyngeal assessment according to the systematic task protocol during FEES (Warnecke et al. 2019).\n\nExclusion Criteria:\n\n\\- Patients who do not sign the consent form",{"count":342,"type":20},350,"This is a non-interventional observational study designed to systematically record the results of routine laryngeal examinations and specific characteristics of dysphagia in patients with neurodegenerative disorders. The results of a fiberoptic \u002F flexible endoscopic evaluation of swallowing (FEES) while performing a structured task protocol will be recorded. If available, laryngeal electromyography (EMG) results will also be recorded. In addition to the examination results, demographic and disease-specific data are collected, and two questionnaires, the Swallowing Disturbance Questionnaire for Parkinson's Disease (SDQ-PD) and the swallowing specific Quality Of Life Questionnaire (SWALQOL), are administered.",[62,168,26,29,92],[62,26,346,29,92,347,348,349,350,351],"Parkinson's disease","Dysphagia","FEES","Laryngeal EMG","Irregular Arytenoid Cartilages Movements","Clinical Biomarker","2025-04-07",{"date":354,"type":36},"2025-04-09",{"date":356,"type":36},"2017-09-01",{"date":125,"type":20},{"name":359,"class":76},"Kliniken Beelitz GmbH",16,{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":136,"sex":15,"minAge":16,"maxAge":368,"enrollmentInfo":369,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":44},"100283059","diagnosing-frontotemporal-lobar-degeneration-100283059","NCT02964637","Diagnosing Frontotemporal Lobar Degeneration","Multimodal Assessment for Predicting Specific Pathological Substrate in Frontotemporal Lobar Degeneration","Inclusion Criteria:\n\n* Participant must have a reliable study partner who can provide an independent evaluation of functioning.\n* Able to read, understand and speak English for neuropsychological testing.\n* All subjects must meet one of these diagnostic criteria (A) probable behavioral variant FTD, (B) MRI-supported non-fluent variant PPA; (C) MRI-supported semantic variant PPA and \\[18F\\]T807 negative (D) probable CBS: using current criteria for CBS(27); (E) PSP: inclusion criteria for PSP are based upon the National Institute of Neurological Disorders and Stroke Society of Progressive Supranuclear Palsy (NINDS-SPSP) (F) FTD-MND\n* Control subjects must have a normal neurological exam, a CDR sum of boxes = 0, and MMSE score equal to or greater than 28\n\nExclusion Criteria:\n\n* Patients with clinical, imaging or CSF A beta\u002F tau profile consistent with AD\n* History of traumatic brain injury, brain tumors, stroke or other neurological or psychiatric disorders that can explain symptoms will be excluded.\n* Premenopausal women will be asked to consent to a pregnancy test prior to each scan as pregnant women will be excluded from study because of potential harm to fetus from PET study.\n* Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.","90 Years",{"count":370,"type":20},100,"To establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical FTLD syndromes",[30,26,373,171,172,374],"Behavioral Variant Frontotemporal Dementia","Amyotrophic Lateral Sclerosis And\u002For Frontotemporal Dementia","2025-03-25",{"date":377,"type":36},"2025-03-30",{"date":379,"type":4},"2015-08",{"date":381,"type":20},"2026-12",{"name":306,"class":76},{"id":384,"slug":385,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":11,"sex":15,"minAge":389,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":392,"conditions":393,"keywords":411,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":44},"100531692","nyscf-scientific-discovery-biobank-100531692","NCT06203106","NYSCF Scientific Discovery Biobank","Inclusion Criteria:\n\n* Age 30 days or older.\n* Diagnosis and\u002For medical history of a condition, disease, genetic background, or trait of interest or healthy control.\n* Adults with decisional capacity must provide written informed consent unless physical limitations preclude signing.\n* Adults without decisional capacity to consent must a have diagnosis of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease and Related Dementias (AD\u002FADRD); Batten Disease, Corticobasal Degeneration (CBD), Dementia, Frontotemporal Dementia (FTD), Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson's Disease (PD), Parkinsonism, and\u002For Progressive Supranuclear Palsy, and must provide assent; a legally authorized representative (LAR) must also provide written informed consent.\n* Minors undergoing skin collection for research purposes must have a condition, disease, genetic background, or trait of interest and parental\u002Fguardian consent.\n* Minors undergoing blood, and\u002For saliva collection for research purposes may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent\u002Fguardian to provide consent.\n* Minors transferring biological samples and associated data from a procedure outside of the research may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent\u002Fguardian to provide consent.\n\nExclusion Criteria:\n\n* Wards of the state.\n* For prospective skin samples: history of keloid formation, coagulation disorder, or allergy to the anesthetic.\n* For prospective blood samples: history of coagulation disorder.\n* For all prospective sample collections: 1) Subjects who refuse to adhere to NYSCF's and\u002For a collection site's safety protocol(s) will be excluded; 2) Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.","30 Days",{"count":391,"type":20},10000,"The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use.\n\nThrough this research, researchers hope to identify future treatments or even cures for the major diseases of our time.",[105,25,108,394,395,396,173,109,24,323,110,116,62,168,397,26,398,399,400,401,402,403,404,405,406,407,408,409,410],"Alzheimer Disease, Early Onset","Alzheimer Disease, Late Onset","Batten Disease","Parkinson's Disease and Parkinsonism","INAD","Diabetes","Diabetes Mellitus","Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1","Macular Degeneration","Ovarian Cancer","Cervical Cancer","Uterine Cancer","Vaginal Cancer","Vulvar Cancer","PTSD","Post Traumatic Stress Disorder",[105,25,108,396,173,109,24,323,110,116,62,168,412,26,398,399,413,414,403,415,404,405,406,407,408,409,410],"Parkinsonism","Diabetes Type 1","Diabetes Type 2","Women's Reproductive Cancer","2025-02-27",{"date":418,"type":36},"2025-03-03",{"date":420,"type":36},"2022-11-10",{"date":422,"type":20},"2045-11-10",{"name":424,"class":76},"New York Stem Cell Foundation Research Institute",{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":315,"enrollmentInfo":432,"targetDuration":4,"studyType":56,"phases":434,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":129},"100528533","phase-2-the-nadapt-study-a-randomized-double-blind-trial-of-nad-replenishment-therapy-for-atypical-parkinsonism-100528533","NCT06162013","The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism","NADAPT","Inclusion Criteria:\n\n1. Participant must understand the nature of the study and be able to provide written, informed consent.\n2. Male or female aged 30-85 years at baseline.\n3. 123I-Ioflupane dopamine transporter imaging (DaTSCAN) or FDOPA- PET has been performed. A negative DaTSCAN cannot be more than two years old at baseline.\n4. Meet the MDS criteria for possible or probable PSP; or\n5. Meet the MDS criteria for clinically possible or probable MSA; or\n6. Meet the consensus criteria for probable or possible CBS.\n7. A baseline PSPRS score of \\\u003C40 for PSP, or baseline UMSARS score \\\u003C 3 on items: 1, 2, 7-9.\n8. Score ≥ 20 on the Mini-Mental State Examination (MMSE) at screening.\n9. Able to ambulate independently or with assistance defined as the ability to take at least 5 steps with a walker (guarding is allowed provided there is no contact) or the ability to take at least 5 steps with the assistance of another person who can only have contact with one upper extremity.\n\nExclusion Criteria:\n\n1. Insufficient fluency in local language to complete neuropsychological and functional assessments.\n2. Evidence of differential diagnoses to PSP, MSA or CBS including: PD; dementia with Lewy bodies; Alzheimer's disease; motor neuron disease; history of repeated and\u002For major stroke; history of repeated and\u002For severe brain or spinal cord; history of neuroleptic use (except quetiapine) for prolonged period within the last 6 months; history of severe encephalitis; street drug-related parkinsonism; vascular parkinsonism; familial PSP, FTD, or known pathogenic MAPT mutation; prion disease; other neurological disease or MRI findings that could explain the PSP, MSA or CBS symptoms.\n3. Presence of other significant neurological or psychiatric disorders including (but not limited to) psychotic disorders; severe bipolar or unipolar depression; seizure disorder; tumor or other space-occupying lesion.\n4. Treatment with\u002Fuse of NR or any investigational drugs or device, within 90 days of screening.\n5. A history of alcohol or substance abuse within 1 year prior to baseline (Visit 1) and deemed to be clinically significant by the site investigator\n6. Any active neoplastic malignancy (other than non-metastatic dermatological conditions) within two years of the screening visit (Visit 0) or current clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal, or neurological disease. Active neoplastic malignancy is defined as having a known malignant focus and\u002For receiving anti-cancer treatment. For the non-cancer conditions, if the condition has been stable for at least the one year before the screening visit (Visit 0) and\u002For is judged by the site investigator not to interfere with the subject's participation in the study, the subject may be included.\n7. Clinically significant laboratory abnormalities at screening that cannot be corrected to baseline and that is deemed incompatible with study participation by investigator.\n8. History of deep brain stimulator surgery other than sham surgery for deep brain stimulation (DBS) clinical trial.\n9. History of a clinically significant medical condition that would interfere with the subject's ability to comply with study instructions, would place the subject at increased risk, or might confound the interpretation of the study results.\n10. Severe dysphagia with inability to swallow study-drug safely at baseline.",{"count":433,"type":20},330,[435],"PHASE2","Progressive supranuclear palsy (PSP), Multiple system atrophy (MSA) and corticobasal syndrome (CBS) are severe neurodegenerative diseases with rapid progression and no effective treatment. Patients quickly succumb to increasing motor and non-motor symptoms and survival ranges from \\~3 years to \\~10 years.\n\nAlthough PSP, MSA and CBS are rare diseases they constitute a major and mostly unaddressed challenge to health-care providers due to the severity of disease and lack of treatment.\n\nThe main hypothesis for the NADAPT trial is that oral administration of NR can boost cellular NAD levels in the central nervous system of patients with PSP, MSA and CBS, and rectify metabolism and inhibit neurodegeneration, resulting in delayed disease progression and amelioration of symptoms for these patients.\n\nTo test whether NR is a neuroprotective therapy for atypical parkinsonism, the investigators will perform the NADAPT clinical trial. The investigators will include 130 patients with Progressive supranuclear palsy (PSP), 165 patients with Multiple system atrophy (MSA) and an indeterminate number of patients with corticobasal syndrome (CBS). The participants will be stratified by disease into three cohorts and randomized to either 3000mg NR daily or placebo.\n\nThe trial will include patients from all of Norway. Patients will be followed for 78 weeks with both in-clinic visits and decentralized safety measurements and reporting of patient reported outcomes (PROMs). After completion of the 78 weeks follow-up, patients are offered to continue in an open-label NR-only extension study, this extension study will last until follow-up is completed for the last patients in NADAPT.",[26,62,30],"2025-01-09",{"date":440,"type":36},"2025-01-10",{"date":442,"type":36},"2024-03-05",{"date":444,"type":20},"2028-12",{"name":446,"class":76},"Haukeland University Hospital",{"id":448,"slug":449,"hasResults":11,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":56,"phases":456,"briefSummary":457,"conditions":458,"keywords":463,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":44},"100529528","the-use-of-the-cue1cue1-in-people-with-parkinsons-disease-and-related-disorders-100529528","NCT06174948","The Use of the CUE1\u002FCUE1+ in People With Parkinson's Disease and Related Disorders","The Use of the CUE1\u002FCUE1+ Device in People With Idiopathic Parkinson's Disease and Related Disorders: A Feasibility Study","Inclusion Criteria:\n\n* Adults over 18 years old\n* Clinical diagnosis of idiopathic PD and related disorders including progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and vascular Parkinsonism (VaP) as well as atypical dystonias and tremor disorders and Orthostatic Tremor (OT)\n* willing to participate and written consent provided after read the participant information sheet.\n\nExclusion Criteria:\n\nIndividuals with:\n\n* other neurological disorders excluding idiopathic PD, related disorders such PSP, MSA, CBD, and VaP as well as atypical dystonias and tremor disorders, affecting movement, balance and gait\n* metabolic or autoimmune disorders affecting movement, balance and gait\n* acute orthopaedic disorders influencing balance control and gait\n* audiovestibular disorders including severe hearing loss\n* visual disturbances, poor eyesight\n* not able to provide written consent form to participate\n* clinical diagnosis of cognitive impairment including dementia or Alzheimer's.\n* Mental impairments (illusions, hallucinations, impulse control disorders) (self-reported)\n\nTechnical contraindications related to CUE1 device:\n\n* implanted metallic or electronic devices usage\n* hypersensitivity to vibrotactile stimulation\n* skin conditions and\u002For open wound in the area of where the device will be positioned (e.g., sternum) if taking medicines for PD or related disorder, then on stable dose of treatment for the last three months.",{"count":455,"type":20},70,[58],"People with Parkinson's disease (PD) commonly experience a range of both motor (e.g., bradykinesia, rigidity, tremor, and postural instability) and non-motor (e.g., fatigue, psychiatric and behavioural disturbances, autonomic dysfunction, cognitive impairment, sleep dysfunction and olfactory loss) features. Currently, it is challenging to alleviate these symptoms with first-line treatment, the medications such as levodopa. The CUE1 is a non-invasive device, which is approved for sale in the UK market as a Class I low risk device. It is worn on the sternum or other part of the body such as the forearm and attaches to the skin via an adhesive patch which has been dermatologically tested and approved.\n\nThe CUE1 delivers pulsing cueing and vibrotactile stimulation to help improve symptoms in people with PD and it has shown to be effective in doing so in previous small case studies. This 9-week feasibility study aims to investigate the feasibility, safety, tolerability and effect of using the CUE1 as an intervention to improve motor and non-motor symptoms in people with PD and related movement disorders. People with clinical diagnosis of idiopathic PD and related disorders including those with progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, orthostatic tremor and vascular Parkinsonism as well as atypical dystonias and tremor disorders aged over 18 years old who have the capacity to provide a written consent form to take part in the study, will receive as intervention to wear the CUE1 device at home, on daily basis while carrying out their activities of daily living. Participants will also have to attend face-to-face appointments of approximately half a day, to discuss how they are getting on with using the CUE1 and complete questionnaires on their symptoms, walking, balance, and movement tests as well as a participant's clinical diary.",[397,26,459,460,62,173,461,462],"Different Types of Tremor Including Essential Tremor","Dystonia","Vascular Parkinsonism","Orthostatic Tremor",[464],"CUE1, Parkinson's disease, movement disorders","2024-11-18",{"date":467,"type":36},"2024-11-21",{"date":469,"type":36},"2024-03-25",{"date":471,"type":20},"2025-03-31",{"name":473,"class":76},"Queen Mary University of London",{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":483,"conditions":484,"keywords":486,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":44},"100565703","utilisation-of-health-services-and-quality-of-life-in-patients-with-atypical-parkinsonian-syndromes-100565703","NCT06645626","Utilisation of Health Services and Quality of Life in Patients With Atypical Parkinsonian Syndromes","UHSQOLAPS","Inclusion Criteria:\n\nPatients and their carers must:\n\n* Be aged 18 or over\n* Have capacity to consent at the beginning of their involvement\n* Have a diagnosis of a neurodegenerative disease which includes progressive supranuclear palsy, corticobasal syndrome and multiple system atrophy but may include other closely related diseases where the presentation is similar, such as Alzheimer's disease where they present with a corticobasal syndrome\n\nExclusion Criteria:\n\n* Patients or carers not meeting the inclusion criteria\n* Patients with static deficits only who do not have a neurodegenerative syndrome.\n* Patients who the principal investigator feels are not suitable to take part due to co-morbidities or participation in other trials.",{"count":482,"type":20},198,"The study will compare health care utilisation and quality of life for patients with progressive supranuclear palsy, corticobasal syndrome and multiple system atrophy in different parts of the region that our specialist clinic operates in with different services as well as in other regions with no specialist clinics. This study aims to investigate which aspects of the service are most beneficial for the patients and to determine the influence of support services and specialty clinics on patients and their carers.",[26,485,62],"Cortico Basal Degeneration",[487,488],"quality of life","health economics","2024-10-15",{"date":491,"type":36},"2024-10-17",{"date":493,"type":36},"2022-10-10",{"date":495,"type":20},"2027-07-15",{"name":497,"class":76},"University Hospital Southampton NHS Foundation Trust",{"id":499,"slug":500,"hasResults":11,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":136,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":506,"targetDuration":508,"studyType":21,"phases":4,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":44},"100334756","quality-of-life-of-the-patient-and-the-burden-of-the-caregiver-in-progressive-supranuclear-palsy-100334756","NCT03638505","Quality of Life of the Patient and the Burden of the Caregiver in Progressive Supranuclear Palsy","Cross-sectional Study of the Factors Determining the Quality of Life of the Patient and the Burden of the Caregiver in Progressive Supranuclear Palsy","Qual-PSP","Inclusion Criteria (patients)\n\nFemale or male, age ≥ 40 years at the time of onset of symptoms\n\n* diagnosis of possible or probable PSP according to the criteria of Litvan (1996b)\n* agreeing to participate in the study\n* subject with no severe cognitive impairment (MMS\\> 20\u002F30)\n* subject who does not have psycho-behavioral comorbidity deemed to be severe enough to make his assessment impossible\n* subject not presenting a measure of legal protection\n\nExclusion Criteria (patients)\n\n* Age \\\u003C40 years at the onset of symptoms\n* Diagnosis other than PSP (including other Parkinsonian syndromes)\n* Presence of another concomitant neurological disease\n* subject with severe cognitive impairment (MMS≤20 \u002F 30)\n* subject presenting psycho-behavioral comorbidities considered sufficiently severe to make it impossible to evaluate\n* subject under legal protection\n* subject not affiliated to a social security scheme\n\nInclusion Criteria (caregivers)\n\n* Female or male, age ≥ 18 years\n* designated by the patient as the person closest to him \u002F her\n* agreeing to participate in the study\n* subject affiliated to a social security scheme\n\nExclusion Criteria (caregivers)\n\n* Age \\\u003C18 years\n* Not designated by the patient as the person closest to him \u002F her\n* Not agreeing to participate in the study\n* subject not affiliated to a social security scheme",{"count":507,"type":20},200,"1 Day","Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease from the parkinsonian syndrome group.\n\nPSP is characterised by the association of a non-doparesponsive parkinsonian syndrome with axial signs. The latter predominantly manifest as a psycho-motor slowness, an apathy and frontal executive deficits. Swallowing impairments may additionally provoke life-threatening situations. Today the treatment is mostly symptomatic as no cure is available. Given the limited treatment options and its clinical characteristics, PSP deeply impact on the patients' quality of life (QoL) as well as on their caregivers'. Nevertheless a limited number of studies have focused on these aspects. A better understaning of the factors determining both patient and cargiver QoL may help optimising their care.\n\nthe principal objective of this study is to identify the determinants of PSP patients' QoL.\n\nThe secondary objectives are : i) to identify the determinants (medical, behavioural, socio-economic, environmental …) of PSP patients' caregivers' QoL and burden ; ii) to validate in French language the QoL scale specific for PSP available in English (PSP-QoL).\n\nThis is a multidisciplinary transversal study. 2 subject groups will be included : i) PSP patients ; ii) caregiver of PSP patients (designated by the patient as being the person closest to them), Data collected : i) from the patient : socio-demographic, social and professionnal environment, clinical (disease duration and severity, neuropsychological evaluation), therapeutic, mood, anxiety, coping, body image, QoL ; ii) from the caregiver: socio-demographic, social and professionnal environment, connection with the patient, data relative to their own health, mood, anxiety, coping, QoL, burden.\n\nProgress : patient information, designation of a caregiver, consent collection, collection of data Statistical analysis : To address the principal objective 'patient' QoL scores will be confronted to the other collected variables (Student's t-test, correlation coefficient). The results will be adjusted to the confounding factors using multivariate analyses.",[26],"2024-01-05",{"date":513,"type":36},"2024-01-08",{"date":515,"type":36},"2019-07-04",{"date":517,"type":20},"2026-07",{"name":519,"class":76},"Assistance Publique Hopitaux De Marseille",{"id":521,"slug":522,"hasResults":11,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":136,"sex":15,"minAge":528,"maxAge":53,"enrollmentInfo":529,"targetDuration":4,"studyType":56,"phases":531,"briefSummary":532,"conditions":533,"keywords":534,"overallStatus":538,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":547},"100528067","early-biomarkers-of-neurodegeneration-in-parkinsonian-syndromes-100528067","NCT06155942","Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes","Early Biomarkers of Neurodegeneration in Parkinsonian Syndromes: Analysis in Very High Field (7T) Brain MRI.","SODIPARK","For Parkinson Disease:\n\nInclusion Criteria:\n\n1. Patients aged between 40 and 80\n2. Fulfilling the diagnostic criteria for MPI (Postuma et al., 2015)\n3. First motor symptom (rigidity, akinesia, tremor) less than 36 months ago\n4. Patient entitled to or affiliated with a social security scheme\n5. Patients who understood, completed and signed the consent form for study participation.\n\nExclusion Criteria:\n\n1. Patient with a neurological disease of the central nervous system other than those studied (including history of stroke, repeated head trauma, documented encephalitis). In case of doubt, this criterion will be left to the discretion of the principal investigator, who is a neurologist.\n2. Contraindications to 7T MRI: presence of an ocular metallic foreign body (accidental shrapnel or other), pacemaker (cardiac simulator) or neurostimulator (pain treatment), cochlear implants or any implanted electronic medical equipment in general, metallic heart valve, vascular clips implanted on a cranial aneurysm.\n3. Claustrophobia or any other condition preventing full MRI.\n4. Montreal Cognitive Assessment (MOCA) test \\\u003C 25\u002F30\n5. Pregnant or breast-feeding woman or protected person (under guardianship, curatorship, deprived of liberty).\n\nFor Progressive Supra-nuclear Palsy:\n\nInclusion criteria:\n\n1. Patients aged 40 to 80\n2. Fulfilling the diagnostic criteria for soPSP (Höglinger et al., 2017) :\n3. First motor symptom (rigidity, akinesia, tremor) or falls or cognitive impairment (frontal syndrome or language disorder or cortico-basal syndrome) occurring less than 36 months ago\n4. Patients benefiting from or affiliated to a social security scheme\n5. Patients who have understood, completed and signed the study participation consent form\n\nExclusion criteria:\n\n1. Patient with a neurological disease of the central nervous system other than those studied (including history of stroke, repeated head trauma, documented encephalitis). In case of doubt, this criterion will be left to the discretion of the principal investigator, who is a neurologist.\n2. Contraindications to 7T MRI: presence of an ocular metallic foreign body (accidental shrapnel or other), pacemaker (cardiac simulator) or neurostimulator (pain treatment), cochlear implants or any implanted electronic medical equipment in general, metallic heart valve, vascular clips implanted on a cranial aneurysm.\n3. Claustrophobia or any other condition preventing MRI.\n4. Pregnant or breast-feeding woman or protected person (under guardianship, curatorship, deprived of liberty).\n\nFor Control group:\n\nInclusion criteria:\n\n1. Subjects aged between 40 and 80\n2. Subjects benefiting from or affiliated with a social security plan\n3. Subjects who have understood, completed and signed the study participation consent form\n\nExclusion criteria:\n\n1. Subjects with a known history of neurological disease of the central nervous system (e.g. Parkinson's disease, Alzheimer's, stroke, brain tumor, multiple sclerosis, amyotrophic lateral sclerosis, repeated head trauma, documented encephalitis, etc.). In case of doubt, this criterion will be left to the discretion of the principal investigator, who is a neurologist.\n2. Contraindications to 7T MRI: presence of an ocular metallic foreign body (accidental shrapnel or other), pacemaker (cardiac simulator) or neurostimulator (pain treatment), cochlear implants or any implanted electronic medical equipment in general, metallic heart valve, vascular clips implanted on a cranial aneurysm.\n3. Claustrophobia or any other condition preventing MRI.\n4. Pregnant or breast-feeding women or protected persons (under guardianship, curatorship, deprived of liberty).","40 Years",{"count":530,"type":20},63,[58],"Parkinson's disease (PD) is the most common degenerative Parkinson's syndrome and is linked, among other things, to the excessive accumulation of an abnormally aggregating protein, alpha-synuclein. Progressive Supranuclear Palsy (PSP) is another Parkinson's syndrome, linked, among other things, to the abnormal accumulation of the protein Tau, and expressed clinically by falls, early cognitive impairment and oculomotor disorders, not present in PD. The onset of these disorders is so gradual that differential diagnosis between the two diseases is only possible at a late stage, on average 3 to 5 years after the onset of symptoms.\n\nTo date, there is a lack of validated imaging biomarkers for diagnosing and monitoring PD and PSP. There is therefore an urgent need for the development of robust biomarkers capable of detecting neurodegeneration at an early stage, in order to aid differential diagnosis as soon as symptoms appear, and to potentially enable these patients to be included in specific therapeutic trials (as these diseases are pathophysiologically different) with potential neuroprotective effects.\n\nThe development of cutting-edge technologies such as 7T MRI, combined with optimized image processing methods, now enable non-invasive in vivo exploration and analysis of these small structures in terms of ion homeostasis (sodium), microstructure (volumetry, amount of iron and neuromelanin) and connectivity.",[168,26],[535,536,295,537],"MRI","Parkinson disease","biomarkers","NOT_YET_RECRUITING","2023-11-24",{"date":541,"type":36},"2023-12-05",{"date":543,"type":20},"2024-01-15",{"date":545,"type":20},"2028-01-15",{"name":519,"class":76},6,{"id":549,"slug":550,"hasResults":11,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":11,"sex":15,"minAge":555,"maxAge":4,"enrollmentInfo":556,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":558,"conditions":559,"keywords":563,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":573,"locationsCount":44},"100224095","modifiable-variables-in-parkinsonism-mvp-100224095","NCT02194816","Modifiable Variables in Parkinsonism (MVP)","Modifiable Variables in Parkinsonism (MVP) [Formerly CAM Care in PD]","Inclusion Criteria:\n\n* Parkinson's disease (PD)\n* Parkinsonism\n* Parkinson-plus syndromes (e.g. Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), Corticobasal degeneration (CBGD), Dementia with Lewy bodies)\n* Must have online access, an email address, basic computer literacy\n* Must be willing to complete online surveys every 6 months for 5 years\n\nExclusion Criteria:\n\n* Inability to read\u002Fwrite English\n* Inability or unwillingness to complete surveys every six (6) months (\\~90 min)","19 Years",{"count":557,"type":20},2000,"We are trying to identify factors associated with improved quality of life and fewer PD symptoms. We are attempting to identify practices, beliefs, and therapies used by individuals who report excellent quality of life, few PD symptoms, and reduced rates of progression. After agreeing to participate, we will ask participants to fill our questionnaires about their experience with PD, their health in general, along with their food intake every six months for five years.",[61,412,104,26,560,173,284,561,562],"Shy-Drager Syndrome","Pick Disease","Olivopontocerebellar Atrophies",[61,564,565,566],"PD","Complementary and Alternative","CAM","2022-03-10",{"date":569,"type":36},"2022-03-25",{"date":571,"type":4},"2012-09",{"date":269,"type":20},{"name":574,"class":76},"Bastyr University"]